Blood test for new breast cancer subtype delays its progression
A blood test that detects when the most common form of breast cancer has become resistant to treatment could double the average time it takes for the disease to progress, from around two and a half to around six months.
01 September 2016
Researchers at The Royal Marsden and The Institute of Cancer Research showed a ‘liquid biopsy’ test, which detects low levels of cancer DNA in the blood, can spot women who will respond poorly to current hormonal treatments and who are more likely to benefit from newer drugs.
The test detects mutations to a gene called oestrogen receptor 1, or ESR1, which indicate that receptors for the female hormone oestrogen in the cancer cells that are usually driven by the hormone have evolved to stay permanently switched on without it – meaning hormonal treatments that block oestrogen production will no longer be effective.
Testing women for the ESR1 mutation allows patients to be separated into two groups, giving clinicians valuable information about which treatment is most likely to be effective.
In the study, published in the Journal of Clinical Oncology, researchers analysed blood samples from a total of 783 women enrolled on two major phase III clinical trials of new treatments for advanced oestrogen receptor positive breast cancer, which accounts for 75% of all cases.
The research, funded by Le Cure, supporters of The Royal Marsden Cancer Charity, the Medical Research Council and the NIHR Biomedical Research Centre (BRC) at The Royal Marsden and ICR sought to find the most effective treatments for breast cancers that have defects in ESR1.
The first trial had compared the effectiveness of a standard aromatase inhibitor drug – exemestane – which works by blocking oestrogen synthesis, with a drug called fulvestrant, which degrades the oestrogen receptor protein so it cannot ‘feed’ the tumour.
Nearly 40% of the 162 patient blood samples available (taken going into the trial) were found to have mutations in the oestrogen receptor. These women responded better to fulvestrant, which delayed progression of the disease for 5.7 months, compared to 2.6 months on exemestane.
For women without ESR1 mutations, both fulvestrant and exemestane treatments had the same effectiveness.
Researchers also looked at a second trial that had compared treatment with fulvestrant and a placebo to fulvestrant and palbociclib. Researchers found 25.3% of patient blood samples had oestrogen receptor mutations going into this trial. But because palbociclib targets different molecules, the patients had the same outcomes regardless of whether or not they had the mutation in the oestrogen receptor.
Breast cancer is the most common cancer in the UK, with 53,969 new cases in 2013 in the UK, and over 11,000 deaths annually. Between 70-80% of breast cancers are oestrogen receptor (ER) positive, and around 40% of ER-positive patients will develop resistance to standard hormone therapy.
Study leader Dr Nicholas Turner, Team Leader in Molecular Oncology at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden said: “Our results show that breast cancer with and without ESR1 mutations are distinct subtypes that respond differently to treatment. These subtypes can be diagnosed simply and cheaply from a blood test, and should be considered for future clinical trials of advanced breast cancer to ensure patients are receiving the best treatment for their cancer.
“For the first time we should able to use a potentially simple test to help us pick the best treatment for women with advanced cancer after their initial treatment has failed. We do need to confirm the results in another trial before we can implement this clinically.”
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, said: “Cancer drug resistance is the biggest challenge we face in defeating the disease. This fantastic new research demonstrates how a relatively simple blood test can be used, not only to detect mutations that could lead to resistance, but to precisely target treatments to the genetic changes in individual tumours as part of personalised, precision therapy.”